Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice

British Journal of Nutrition

Volumn 108, Issue 11, 2012, Pages 2014-2025

  Wang, Chen Dong ^a   Teng, Bao Song ^a   He, Yan Ming ^b   Wu, Jia Sheng ^b   Pan, Deng ^a   Pan, Luan Feng ^a   Zhang, Dan ^b   Fan, Zhao Hua ^b   Yang, Hong Jie ^b   Zhou, Ping ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

db db Mice; Diabetes; Ganoderma lucidum; Protein tyrosine phosphatase 1B

Indexed keywords

ALANINE; AMINO ACID; ASPARTIC ACID; FUDAN YUEYANG GANODERMA LUCIDUM EXTRACT; GANODERMA LUCIDUM EXTRACT; GLUCOSE; GLUTAMIC ACID; GLYCINE; GLYCOGEN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; METFORMIN; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PROTEOGLYCAN; SERINE; STREPTOZOCIN; THREONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; GANODERMA LUCIDUM; GLYCOGEN LIVER LEVEL; HYPERGLYCEMIA; IC 50; IN VIVO STUDY; INSULIN SENSITIVITY; LETHAL DOSE; MALE; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LIVER GLYCOGEN; MALE; MICE; MICE, MUTANT STRAINS; ORGAN SPECIFICITY; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN SUBUNITS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEOGLYCANS; RECEPTOR, INSULIN; REISHI;

GANODERMA LUCIDUM; MUS;

EID: 84866101342     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512000153     Document Type: Article

References (54)

1. Harris M & Zimmet P (1997) Classification of diabetes melli-tus and other categories of glucose intolerance. In International Textbook of Diabetes Mellitus, 2nd ed., pp. 9-23 [K Alberti, P Zimmet and R Defronzo, editors]. Chichester: John Wiley and Sons Limited.
2. Barr AJ, Ugochukwu E, Lee WH, et al. (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352-363.
3. Valentino L & Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71, 713-721.
4. Tonks NK, Diltz CD & Fischer EH (1988) Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem 263, 6722-6730.
5. Goldstein BJ (2002) Protein-tyrosine phosphatase 1B (PTP1B): emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocr Metab 87, 2474-2480.
6. Seely BL, Staubs PA, Reichart DR, et al. (1996) Protein tyro-sine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45, 1379-1385.
7. Zabolotny JM, Haj FG, Kim YB, et al. (2004) Transgenic over-expression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279, 24844-24851.
8. Cromlish WA, Tang M, Kyskan R, et al. (2006) PTP1B-depen-dent insulin receptor phosphorylation/residency in the endocytic recycling compartment of CHO-IR cells. Biochem Pharmacol 72, 1279-1292.
9. Asante-Appiah E & Kennedy BP (2003) Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 284, E663-E670.
10. Saltiel AR (1996) Diverse signaling pathways in the cellular actions of insulin. Am J Physiol Endocrinol Metab 270, E375-E385.
11. Ahmad F, Azevedo JJ, Cortright R, et al. (1997) Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 100, 449-458.
12. Elchebly M, Payette P, Michaliszyn E, et al. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548.
13. Escriva F, Rodriguez AG, Millan EF, et al. (2010) PTP1B deficiency enhances liver growth during suckling by increasing the expression of insulin-like growth factor-I. J Cell Phy-siol 225, 214-222.
14. Van Huijsduijnen RH, Bombrun A & Swinnen D (2002) Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 7, 1013-1019.
15. Park H, Bhattarai BR, Ham SW, et al. (2009) Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors. Eur J Med Chem 44, 3280-3284.
16. Combs AP (2010) Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 53, 2333-2344.
17. Wasser SP & Weis AL (1999) Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19, 65-96.
18. Wasser SP (2011) Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 89, 1323-1332.
19. Seto SW, Lam TY, Tam HL, et al. (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extracct in obese/diabetic (db/db) mice. Phytomedicine 16, 426-436.
20. Meng GL, Zhu HY, Yang SL, et al. (2011) Attenuating effects of Ganodermalucidum polysaccharidesonmyocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. Carbohydr Polym 84, 180-185.
21. Yang BK, Jeong SC, Park JB, et al. (2001) Swimming endurance capacity of mice after administration of exo-polymer produced from submerged mycelia culture of Ganoderma lucidum. J Microbiol Biotechn 11, 902-905.
22. Hikino H & Mizuno T (1989) Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies. Planta Med 55, 385-385.
23. Wachtel-Galor S, Tomlinson B & Benzie IFF (2004) Gano-derma lucidum ('Lingzhi'), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Brit J Nutr 91, 263-269.
24. Teng BS, Wang CD, Yang HJ, et al. (2011) A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J Agr Food Chem 59, 6492-6500.
25. Kobayashi K, Forte TM, Taniguchi S, et al. (2000) The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49, 22-31.
26. Kodama H, Fujita M & Yamaguchi I (1994) Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia 37, 739-744.
27. Folch J, Lees M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497-509.
28. Chernoff J, Schievella AR, Jost CA, et al. (1990) Cloning of a cDNA for a major human protein-tyrosine-phosphatase. Proc Natl Acad Sci U S A 87, 2735-2739.
29. Bialy L & Waldmann H (2005) Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew Chen Int Ed Engl 44, 3814-3839.
30. Seiner DR, Labutti JN & Gates KS (2007) Kinetics and mechanism of protein tyrosine phosphatase 1B inactivation by acrolein. Chem Res Toxicol 20, 1315-1320.
31. Liu DG, Gao Y, Voigt JH, et al. (2003) Acylsulfonamide-con-taining PTP1B inhibitors designed to mimic an enzyme-bond water of hydration. Bioorg Med Chem Lett 13, 3005-3007.
32. Liu GX, Tan JZ, Niu CY, et al. (2006) Molecular dynamics stimulations of interaction between protein-tyrosine phos-phatase 1B and a bidentate inhibitor. Acta Pharmacol Sin 27, 100-110.
33. Asante-Appiah E, Patel S, Dufresne C, et al. (2002) The structure of PTP1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 41, 9043-9051.
34. Bartlett AH & Park PW (2010) Proteoglycans in host-pathogen interactions: molecular mechanism and therapeutic implications. Exp Rev Mol Med 12, 1-22.
35. Bach-Knudsen KE & Jørgensen H (2007) Impact of wheat and oat polysaccharides provided as rolls on the digestion and absorption processes in the small intestine of pigs. J Sci Food Agr 87, 2399-2408.
36. Liu G, Xin ZL, Liang H, et al. (2003) Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyr-osine binding site with non-carboxylic acid-containing ligands. J Med Chem 46, 3437-3440.
37. Glover NR & Tracey AS (1999) Modeling studies of the interaction between the insulin receptor kinase domain and protein tyrosine phosphatase 1B. J Am Chem Soc 121, 3579-3589.
38. Glover NR & Tracey AS (1999) Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B. Biochemistry 38, 5256-5271.
39. Tagami S, Sakaue S, Honda T, et al. (2002) Effects of trogli-tazone on skeletal muscle and liver protein tyrosine phos-phatase activity in insulin-resistant Otsuka Long-Evans Tokushima fatty rats. Curr Ther Res 63, 572-586.
40. Tagami S, Honda T, Yoshimura H, et al. (2002) Triglitazone ameliorates abnormal activity of protein tyrosine phospha-tase in adipose tissues of Otsuka Long-Evans Tokushima fatty rats. Tohoku J Exp Med 197, 169-181.
41. 2/2 mice. J Biol Chem 280, 15038-15046.
42. Fukuda S, Ohta T, Sakata S, et al. (2010) Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551. Diabetes Obes Metab 12, 299-306.
43. y mice. J Nutr Biochem 22, 71-78.
44. Mao XQ, Yu F, Wang N, et al. (2009) Hypoglycemic effect of polysaccharide enriched extract of Astragalus membrana-ceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism. Phytomedicine 16, 416-425.
45. Wu Y, Ou-Yang JP, Wu K, et al. (2005) Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacol Sin 26, 345-352.
46. Bosch F, Pujol A & Valera A (1998) Transgenic mice in the analysis of metabolic regulation. Annu Rev Nutr 18, 207-232.
47. Kim MK, Chae YN, Son MH, et al. (2008) PAR-5359, a well-banlanced PPARa/b dual agonist, exhibits equivalent anti-diabetic and hypolidemic activities in vitro and in vivo. Eur J Pharmacol 595, 119-125.
48. Bhavsar SK, Singh S, Giri S, et al. (2009) Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression. J Ethnopharmacol 124, 426-433.
49. Matveyenko AV, Dry S, Cox HI, et al. (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Diabetes 58, 1604-1615.
50. Bhattarai BR, Ko JH, Shrestha S, et al. (2007) Inhibition of IKK-b: a new development in the mechanism of the anti-obesity effects of PTP1B inhibitors SA18 and SA32. Bioorg Med Chem 20, 1075-1077.
51. Garber AJ (2002) Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab 4, S5-S12.
52. Tao R, Ye F, He YB, et al. (2009) Improvement of high-fat-diet-induced metabolic syndrome by a compound from Balanophora polyandra Griff in mice. Eur J Pharmacol 616, 328-333.
53. Yamabe N, Noh JS, Park CH, et al. (2010) Evaluation of lognan, iridoid glycoside from Corni fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice. Eur J Pharmacol 648, 179-187.
54. Gum RJ, Gaede LL, Koterski SL, et al. (2003) Redution of protein phosphatase 1B increase insulin-dependent signaling in ob/ob mice. Diabetes 52, 21-28.